autologous platelet-rich plasma (Nadezhda Women's Health Hospital)

Autologous platelet-rich plasma (PRP) is a concentrated preparation of platelets derived from a patient's own peripheral blood through centrifugation. In the clinical context of Nadezhda Women's Health Hospital, it is utilized as an intraovarian injection for women diagnosed with poor ovarian response (POR) according to the Bologna criteria. The PRP is typically activated with calcium gluconate to induce the release of a variety of growth factors, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), and fibroblast growth factor (FGF). These factors are thought to enhance ovarian function by promoting neoangiogenesis, reducing oxidative stress, and potentially activating dormant follicles, thereby improving ovarian reserve markers (such as AMH and AFC) and the quality of oocytes and embryos in assisted reproductive technology (ART) cycles.

Brand names

Arthrex ACP Max

Other names

PRPautologous ovarian PRPintraovarian platelet-rich plasmaautologous platelet-rich plasma-Nadezhda Women's Health Hospital-poor ovarian response